Women in Science
As well as CEO, Judy Chou is also president, and her role is centered around addressing unmet medical needs in immunological diseases.
Netris Pharma’s lead product was awarded €1.2 million Eurostar grant to make an antibody therapeutic to treat arthritis and metastatic bone cancer pain.
The drug, intended for adult patients with moderate-to-severe systemic lupus erythematosus, is the only new therapy approved for SLE in more than a decade.
The clinical research solutions firm is joining forces with pharma giant Eli Lilly to manage mobile research of the monoclonal antibody LY-CoV555.
Vir Biotechnology turns to WuXi to support development and commercialization of an antibody-based potential treatment for the coronavirus.
Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Innate Pharma stops dosing new patients in clinical trial amid problems at manufacturing partner.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
Immunomedics to leverage Ideagen’s PleaseReview software service to support documentation management of its ADC development projects.
Wacker licenses E. coli based production strain to PhaseBio for the manufacture of antibody fragment.
Twist Bioscience, a synthetic DNA provider, enters a strategic collaboration with LakePharma to bolster antibody discovery and optimization for biologic drug development.
Ligand Pharmaceuticals enters an agreement with Genagon to provide access to its drug development platform capable of producing fully human antibodies.
The clinical-stage biotechnology company Allogene has licensed Ablexis’ antibodies for the use of CAR-T therapy research and development.
Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.
Charles River and Distributed Bio are creating an integrated antibody discovery and development platform as part of an exclusive partnership.
Abzena has signed an antibody humanization agreement with Tmunity Therapeutics a clinical stage T cell therapy company.
Sanofi is set to acquire its antibody-fragment tech partner Ablynx for €3.9bn ($4.8bn).
Immunoprecise Antibodies is set to purchase QVQ Holding BV in its most recent acquisition that further increases its antibody services.
Shark antibodies are an attractive way to deliver biologics to the brain, says Ossianix which is using its blood-brain barrier (BBB) crossing technology in collaboration with Lundbeck.
Mucosis B.V. has started a volunteer study of SynGEM, a respiratory syncytial virus (RSV) vaccine formulated for nasal delivery.
Almac is coupling tiny shark proteins to a cancer-killing warhead to develop an oncology drug, saying their small size makes for easy conjugation.
Adimab says there are more antibody discovery partnerships to come following deals inked with Celgene and Innovent.
FDA: Risk-based Immunogenicity Testing will Boost Protein Development
The US FDA says draft guidelines on risk-based immunogenicity testing of protein drugs will encourage the pharma industry to continue development efforts.
WuXi PharmaTech has formed an antibody discovery partnership with US transgenic animals firm Open Monoclonal Technology (OMT).
SGS’ has opened a new cell-based assay laboratory in Poitiers, France in its latest European, biopharma-focused investment.
Evotec and 4-Antibody have teamed up to offer a new antibody testing service.
Outsourcing brings Neovacs to cusp of Ph III partnership
Neovacs is looking to partner for late stage development after using its outsourced model to bring multiple products to Phase II.
NIAID awards $15.5m to needle-free dengue vaccine
Inviragen and PharmaJet have been awarded a $15.5m (€11.1m) contract by the US NIAID to develop a needle-free dengue vaccine.
ForteBio unleash Protein G biosensor for Ab drug discovery on Octet instrumentation
The life sciences company, ForteBio, has launched its Dip and Read Protein G biosensor, designed for the fast-track analysis of specific biomolecular interactions of various types of the antibody molecule, mammalian immunoglobulin.
Octapharma licenses new BAC purification ligand
Bioprocess purification chromatography tech wins BAC new deal after Swiss protein maker Octapharma licenses it for commercial-scale manufacture.
Concerns about the quality and capabilities of Baxter’s manufacturing operations have led to Halozyme issuing a notice of breach and stating it may terminate their Hylenex relationship.
Thermo buys Affinity BioReagents
Thermo Fisher Scientific has followed up its acquisition of Open Biosystems with the purchase of antibody experts Affinity BioReagents to further bolster its protein research offering.
PER.C6 platform achieves highest ever yield
The PER.C6 cell culture-based antibody production platform has
achieved a new record yield of 27 grams of IgG antibody per litre,
bettering the 15 gram per litre mark that was reported earlier in
Millipore system makes Western blots a breeze
Life sciences equipment company Millipore says its new protein
detection system, SNAP i.d, can improve the time it takes to carry
out Western blots by as much as 80 per cent compared to
conventional immunodetection methods.
Regeneron helps make Sanofi VelocImmune to its 'weak' pipeline
Sanofi-Aventis recently admitted it needed to increase the number
of biotech compounds in its pipeline and now, true to its word, the
French pharma heavyweight has signed a big antibody deal with US
Ablynx decides to go it alone with camel-based mini-antibodies
Ablynx, a biopharma firm that specialises the potentially lucrative
sector of miniature antibodies, has announced it plans to launch on
the stock market this year.
F-star antibodies reaching for the sky
F-star is free to push forward with its plan to 'take
antibody-based therapeutics to the next level' having secured
venture capitalist backing.
Biotest scoops up ailing Nabi's biologics unit
German firm Biotest has bought up Nabi Biopharmaceuticals biologics
division in a multi-million Euro deal, less than three months after
the unit was created following Nabi restructuring efforts.
Antibody alternatives continue to pull in the cash
Ablynx, one of the two main players in the miniature antibody
sector, has signed 'by far' the biggest deal in its history, to
help Boehringer Ingelheim develop up to ten so called 'Nanobodies'.
Synthetic MAb purification tech edges closer to market
The UK arm of biopharma company ProMetic has hit a milestone with
its breakthrough synthetic molecule solution for protein
Antibody rival drawing investors to Molecular Partners
An award-winning therapeutic protein technology, touted as superior
to antibodies, has attracted venture capitalist investment for its
owners, the Swiss biotech Molecular Partners.
Ablynx technology rivals GSK's mini-antibodies
Belgian biopharma Ablynx has announced its lead miniature antibody
has shown good interim results in a first-in-man trial, leaving it
one step ahead of GlaxoSmithKline (GSK).
GSK reveals details of $2bn antibody
GlaxoSmithKline (GSK) outlined more details on the mechanism of its
anticancer drug ofatumumab - an antibody that was the subject of
the biggest ever pharma licensing deal.
Covance ranks New England Peptide first in quality test
A US-based peptide provider, New England Peptide, has ranked first
in a recent peptide quality validation study conducted by Covance.
Drugs moving into the clinic: 7
The seventh in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
Breakthrough in plant seeds for drug production
Researchers in Belgium have succeeded in using plant seeds to
produce high yields of proteins that bear a strong resemblance to
human antibodies, thus bringing the possibility of using plant
systems as an inexpensive alternative to...
Duff reports on clinical trial safety
Experts have made 22 recommendations to improve the safety of Phase
I drug trials after the disastrous trial that nearly killed six
Wyeth enters into Nanobodies agreement with Ablynx
Wyeth Pharmaceuticals has announced they have entered into
collaboration with Ablynx in a deal, which aims to commercialise a
class of antibody-derived therapeutic proteins targeting diseases
that include oncology and Alzheimer's...